Calistoga Drug Shrinks Tumors in Lab Studies

Xconomy Seattle — 

Seattle-based Calistoga Pharmaceuticals said that its lead experimental drug, CAL-101, killed cancer cells in lab studies of multiple blood malignancies. The drug is designed to block a marker inside cells called the PI3 kinase pathway, that is thought to play a key role in tumor cell growth, survival, and migration. The findings were delivered in an oral presentation at the American Society of Hematology meeting in San Francisco.

By posting a comment, you agree to our terms and conditions.

Comments are closed.